 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...192193194195196197198199200201202203204» |
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: TURA: Targeted Ultrasound in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 3, 2014
P4, N=400, Recruiting, Sponsor: University of Leeds
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: MB: Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD) (clinicaltrials.gov) - Feb 3, 2014
P=N/A, N=25, Completed, Sponsor: Martin Storr
Recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Trial termination, HEOR: Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=30, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Recruiting --> Terminated; This study was prematurely terminated due to low enrollment and not for safety reasons.
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, HEOR: Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=30, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Terminated; This study was prematurely terminated due to low enrollment and not for safety reasons. N=75 --> 30
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Trial withdrawal: SPIRIT A1: Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Jan 20, 2014
P3, N=0, Withdrawn, Sponsor: Eli Lilly and Company
N=75 --> 30 Not yet recruiting --> Withdrawn
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Enrollment change: SPIRIT A1: Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Jan 20, 2014
P3, N=0, Withdrawn, Sponsor: Eli Lilly and Company
Not yet recruiting --> Withdrawn N=408 --> 0
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=4626, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=408 --> 0 Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open, PK/PD data: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jan 15, 2014
P2, N=30, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: BROCAII: Bone Resorption, Osteoclastogenesis and Adalimumab (clinicaltrials.gov) - Jan 12, 2014
P4, N=120, Recruiting, Sponsor: Université de Sherbrooke
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: APPRECIA: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (clinicaltrials.gov) - Jan 12, 2014
P3, N=84, Active, not recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jan 6, 2014
P3, N=425, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Observational data, P4 data: STRIVE: Juvenile Idiopathic Arthritis (JIA) Registry (clinicaltrials.gov) - Dec 22, 2013
P=N/A, N=800, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Plivensia (sirukumab) / J&J
New P3 trial, Monotherapy: SIRROUND-H: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA (clinicaltrials.gov) - Dec 22, 2013
P3, N=510, Recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Dec 18, 2013
P3, N=200, Recruiting, Sponsor: AbbVie
- | Humira (adalimumab) / Eisai, AbbVie
New P2 trial, PK/PD data: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Dec 17, 2013
P2, N=30, Recruiting, Sponsor: AbbVie
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Optimising adalimumab treatment in psoriasis with concomitant methotrexate. (EUDRACT) - Dec 11, 2013
P4, N=100, Ongoing, Sponsor: Academic Medical Center
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: BROCA: Bone Resorption, Osteoclastogenesis and Adalimumab (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=28, Completed, Sponsor: Université de Sherbrooke
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Initiation date: Jul 2008 --> Jan 2009
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 27, 2013
P3, N=60, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Initiation date: Jul 2008 --> Jan 2009 Active, not recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Special Investigation (Long-term Investigation) in Patients With Crohn's Disease (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, HEOR: Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment) (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=2000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, HEOR, Real-world evidence, Real-world: Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=152, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, HEOR: Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice (clinicaltrials.gov) - Nov 17, 2013
P=N/A, N=460, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=700 --> 460
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Nov 17, 2013
P=N/A, N=266, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=700 --> 460 N=72 --> 266
- ||||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: APPRECIA: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (clinicaltrials.gov) - Nov 14, 2013
P3, N=84, Active, not recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
N=72 --> 266 Initiation date: Dec 2011 --> Jun 2012
- | Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: ADACAL: Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (clinicaltrials.gov) - Nov 14, 2013
P3, N=160, Recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Initiation date: Dec 2011 --> Jun 2012 Initiation date: Mar 2012 --> Oct 2012
- || Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients (clinicaltrials.gov) - Nov 14, 2013
P3, N=102, Recruiting, Sponsor: Sara Varea
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open: ADACAL: Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (clinicaltrials.gov) - Nov 14, 2013
P3, N=160, Recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Initiation date: Mar 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Nov 12, 2013
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Nov 7, 2013
P4, N=600, Recruiting, Sponsor: Pfizer
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab (clinicaltrials.gov) - Nov 3, 2013
P2, N=88, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: PIONEER I: Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Oct 29, 2013
P3, N=309, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Initiation date: Sep 2010 --> Nov 2011
- Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Biomarker: Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD) (clinicaltrials.gov) - Oct 28, 2013
P=N/A, N=60, Recruiting, Sponsor: Erasmus Medical Center
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Combination therapy: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) (clinicaltrials.gov) - Oct 20, 2013
P4, N=100, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
Initiation date: Sep 2010 --> Nov 2011 Initiation date: Dec 2012 --> Jun 2013
- ||| Humira (adalimumab) / AbbVie
Trial completion: Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (clinicaltrials.gov) - Oct 16, 2013
P=N/A, N=83, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Dec 2012 --> Jun 2013 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation) (clinicaltrials.gov) - Oct 9, 2013
P=N/A, N=250, Recruiting, Sponsor: AbbVie
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New P4 trial, HEOR: Evaluation of Health Costs and Resource Utilization (clinicaltrials.gov) - Oct 8, 2013
P4, N=160, Not yet recruiting, Sponsor: University of Western Ontario, Canada
- ||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease (clinicaltrials.gov) - Oct 7, 2013
P3, N=28, Recruiting, Sponsor: AbbVie
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease (clinicaltrials.gov) - Oct 6, 2013
P3, N=28, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- GSK2800528 / GSK
Enrollment closed: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. (clinicaltrials.gov) - Oct 3, 2013
P1, N=45, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Humira (adalimumab) / AbbVie
Biomarker, Enrollment change: Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) (clinicaltrials.gov) - Sep 30, 2013
P4, N=69, Completed, Sponsor: University Hospital, Tours
Recruiting --> Active, not recruiting N=100 --> 69
- Humira (adalimumab) / AbbVie
Biomarker, Trial completion: Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) (clinicaltrials.gov) - Sep 30, 2013
P4, N=69, Completed, Sponsor: University Hospital, Tours
N=100 --> 69 Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 29, 2013
P3, N=60, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Trial completion: ADIBD: Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=310, Completed, Sponsor: Stanford University
Recruiting --> Completed Recruiting --> Completed
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Trial initiation date: SPIRIT A1: Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Sep 22, 2013
P3, N=0, Withdrawn, Sponsor: Eli Lilly and Company
Recruiting --> Completed Initiation date: Sep 2013 --> Jul 2014
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Special Investigation in Patients With Ulcerative Colitis (clinicaltrials.gov) - Sep 19, 2013
P=N/A, N=1500, Recruiting, Sponsor: AbbVie
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
Initiation date: Sep 2013 --> Jul 2014 N=1814 --> 1360
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation (clinicaltrials.gov) - Sep 12, 2013
P4, N=50, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=1814 --> 1360 Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie, Tavalisse (fostamatinib) / Rigel, Kissei
Trial termination, Monotherapy: OSKIRA -4: Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 5, 2013
P2b, N=390, Terminated, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Aug 26, 2013
P3, N=274, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Terminated; AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals. Active, not recruiting --> Completed